Are you Dr. Bajaj?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 1 invite waiting! - Read the latest clinical news, personalized to your specialty.
Office
9500 Euclid Ave
"# A-53"
Cleveland, OH 44195Phone+1 216-445-0682Fax+1 216-445-1656
Summary
- Dr. Harpreet Bajaj, MD is an endocrinologist in Cleveland, Ohio.
Publications & Presentations
PubMed
- Efficacy and hypoglycaemia outcomes with once-weekly insulin icodec versus once-daily basal insulin in individuals with type 2 diabetes by kidney function: A post hoc ...Peter Rossing, Malik Benamar, Alice Y Y Cheng, Bharath Kumar, Christian Laugesen
Diabetes, Obesity & Metabolism. 2025-04-01 - 2 citationsInsulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment.Carol Wysham, Harpreet S Bajaj, Stefano Del Prato, Denise Reis Franco, Arihiro Kiyosue
The New England Journal of Medicine. 2024-12-12 - The User's Guide to the Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update., Sonia Butalia, Harpreet S Bajaj, Rahul Jain, Karen Leung
Canadian Journal of Diabetes. 2024-10-01
Press Mentions
Novo Nordisk Tees up Phase 3 Trial for Once-Weekly InsulinSeptember 24th, 2020- Switching to Investigational Once-Weekly Insulin Icodec from Other Basal Insulins Demonstrated to Be Efficacious and Well-Tolerated for People with Type 2 Diabetes in Phase 2 TrialSeptember 22nd, 2020
- MACE Benefits with Dapagliflozin Improve with Disease DurationMarch 4th, 2020
- Join now to see all
